Results 11 to 20 of about 4,565 (192)

A Case of Lung Adenocarcinoma With Concurrent EGFR Mutation and ALK Fusion Combined With Literature Review. [PDF]

Clin Case Rep
ABSTRACT This case underscores the critical importance of retesting for resistant mechanisms, such as EML4‐ALK fusion, in patients with EGFR‐mutant lung adenocarcinoma who experience rapid progression on EGFR‐tyrosine kinase inhibitor (TKI) therapy. Early identification of such co‐alterations and an immediate switch to alectinib can lead to rapid and ...
Chen Y, Qi F, Zeng Y, Tan J, Hu M, Zhang H, Zhang T.   +6 more
europepmc   +2 more sources

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Clinical and Translational Science, 2022
The ALK in Lung Cancer Trial of brigAtinib in First Line (ALTA‐1L) compared brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK) inhibitor‐naive patients with ALK+ non‐small cell lung cancer (NSCLC).
Neeraj Gupta, Karen L. Reckamp, David R. Camidge, Huub J. Kleijn, Aziz Ouerdani, Francesco Bellanti, John Maringwa, Michael J. Hanley, Shining Wang, Pingkuan Zhang, Karthik Venkatakrishnan   +10 more
doaj   +1 more source

Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study [PDF]

, 2022
Circulating tumor DNA; Non–small cell lung cancer; Tumor biomarkerADN tumoral circulante; Cáncer de pulmón de células no pequeñas; Biomarcador tumoralADN tumoral circulant; Càncer de pulmó de cèl·lules no petites; Biomarcador tumoralIntroduction ...
Ahn, Mj, Barlesi, F, Bearz, A, de Marinis, F, Felip, E, Garrido, P, Ignatius Ou SH,, Kim, Dw, Kim, Es., Kim, Sw, Lin, Hm, Liu, G, Mazieres, J, Migliorino, Mr, Mok, T, Morabito, A, Nishio, M, Niu, H, Novello, S, Pérol, M, Yang, H, Zhang, P, Zhou, C   +22 more
core   +4 more sources

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. [PDF]

, 2020
Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
Al-Holou, Wajd, Armas, Octavio, Kubota, Takafumi, Nagasaka, Misako, Ou, Sai-Hong Ignatius, Raval, Kunil, Robinette, Natasha, Zhu, Viola W   +7 more
core   +1 more source

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

BMC Cancer, 2023
Background The ALTA-1L study compared brigatinib with crizotinib in untreated ALK-rearranged non-small cell lung cancer (NSCLC) patients, demonstrating the efficacy of brigatinib.
Kazushige Wakuda, Hirotsugu Kenmotsu, Yuki Sato, Atsushi Nakamura, Hiroaki Akamatsu, Motoko Tachihara, Satoru Miura, Toshihide Yokoyama, Keita Mori, Kazuhiko Nakagawa, Nobuyuki Yamamoto   +10 more
doaj   +1 more source

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors [PDF]

, 2023
Anaplastic lymphoma kinase; Brigatinib; Drug-drug interactionQuinasa del linfoma anaplásico; Brigatinib; Interacción fármaco-fármacoQuinasa del limfoma anaplàstic; Brigatinib; Interacció medicament-medicamentBrigatinib is a next-generation anaplastic ...
D’Arcangelo, Manolo, Felip Font, Enriqueta, Garrido, Pilar, Hanley, Michael J, Ye, Meng, Zhu, Jiaxi   +5 more
core   +1 more source

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. [PDF]

, 2016
Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(2;5; p23;q35) that produces the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase).
Ambrogio, Chiara, Bombelli, Silvia, Casati, Cesare, Ceccon, Monica, Chiarle, Roberto, Compagno, Mara, Di Giacomo, Filomena, Gambacorti-Passerini, Carlo, Giudici, Giovanni, Manazza, Andrea D, Mastini, Cristina, Menotti, Matteo, Merlo, Maria Elena Boggio, Mologni, Luca, Poggio, Teresa, Rigolio, Roberta, Turner, Suzanne D, Varesio, Lydia M, Voena, Claudia   +18 more
core   +3 more sources

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer [PDF]

, 2021
Brigatinib; NSCLC; Inhibidor de la tirosina quinasaBrigatinib; NSCLC; Inhibidor de la tirosina quinasaBrigatinib; NSCLC; Tyrosine kinase inhibitorBackground The next-generation ALK inhibitor brigatinib is approved for use in patients with ALK inhibitor ...
Brustugun, Odd Terje, Cadranel, Jacques, Felip Font, Enriqueta, Garassino, Marina Chiara, Griesinger, Frank, Popat, Sanjay   +5 more
core   +1 more source

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study [PDF]

, 2022
Anaplastic lymphoma kinase; First line; Tyrosine kinase inhibitorCinasa del linfoma anaplásico; Primera línea; Inhibidor de la tirosina quinasaQuinasa del limfoma anaplàsic; Primera línia; Inhibidor de la tirosina quinasaBackground Brigatinib is a next ...
Ahn, Myung-Ju, Felip Font, Enriqueta, Han, Ji-Yu, Hochmair, Maximilian J., Kim, Hye R., Li, Jacky Y.C., Yang, James C. H.   +6 more
core   +1 more source

Brigatinib-repurposed chemo-photodynamic therapy nanoplatform via effective apoptosis against colorectal cancer

Materials & Design, 2023
Colorectal cancer (CRC), a malignancy with a relatively high fatality rate, still poses a growing global public health challenge due to the lack of well-established and effective treatment strategies.
Miao Su, Hailong Tian, Li Zhou, Qiong Li, Shuqi Wang, Canhua Haung, Edouard C. Nice, Shaojiang Zheng, Jingquan Li   +8 more
doaj   +1 more source